3-(4-methylpiperazin-1-yl)-N-propylpropan-1-amine | 1042528-95-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 3-(4-methylpiperazin-1-yl)-N-propylpropan-1-amine
• CAS: 1042528-95-9
• 化学式: C₁₁H₂₅N₃
• 分子量: 199.34
• InChiKey: ADGRWTCKHBKSBC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  14
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  18.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(4-methylpiperazin-1-yl)-N-propylpropan-1-amine 在 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 三乙胺 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 (2S)-3-(4-chlorophenyl)-2-[(4-methoxy-2,3,6-trimethylphenyl)sulfonylamino]-N-[3-(4-methylpiperazin-1-yl)propyl]-N-propylpropanamide
  参考文献：
  名称：

  The discovery of novel 8-azabicyclo[3.2.1]octan-3-yl)-3-(4-chlorophenyl) propanamides as vasopressin V1A receptor antagonists

  摘要：

  The discovery of a novel series of 8-azabicyclo[3.2.1] octan-3-yl)-3-(4-chlorophenyl) propanamide antagonists of the vasopressin V-1A receptor is disclosed. Compounds 47 and 48 were found to be high affinity, selective vasopressin V-1A antagonists. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.02.096

文献信息

• Multicomponent Degradable Cationic Polymers
  申请人：Green Jordan J.

  公开号：US20120128782A1

  公开（公告）日：2012-05-24

  Degradable polymers were synthesized that self-assemble with DNA to form particles that are effective for gene delivery. Small changes to polymer synthesis conditions, particle formulation conditions, and polymer structure provides significant changes to efficacy in a cell-type dependent manner. Polymers presented here are more effective than commercially available materials, such as LIPOFECTAMINE 2000 ™, FUGENE®, or polyethylenimine (PEI), for gene delivery to cancerous fibroblasts or human primary fibroblasts. The presently disclosed materials may be useful for cancer therapeutics and regenerative medicine.
• QUINDOLINE COMPOUNDS AND USES THEREOF
  申请人：Arizona Board of Regents on Behalf of the University of Arizona

  公开号：US20220098210A1

  公开（公告）日：2022-03-31

  This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a quindoline (or similar) structure which function as stabilizers of G-quadruplex (G4) formation, and their use as therapeutics for the treatment of cancer (e.g., castration-resistant prostate cancer), and other conditions mediated by G4 stabilization.
• US8992991B2
  申请人：——

  公开号：US8992991B2

  公开（公告）日：2015-03-31